ライフサイエンスコーパス: stem cell mobilization

1 ce with AMD3100 (plerixafor) and its role in stem cell mobilization.

2 on of HSCs into the hepatic parenchyma after stem cell mobilization.

3 inical trials evaluating novel approaches to stem cell mobilization.

4 f relapse, toxicity, mechanism of action, or stem cell mobilization.

5 Fifty patients were enrolled and underwent stem cell mobilization.

6 00-mediated and G-CSF-mediated hematopoietic stem cell mobilization.

7 eutrophil chemoattraction, angiogenesis, and stem cell mobilization.

8 gnaling networks that underlie hematopoietic stem cell mobilization.

9 for HIV infection and plerixafor (CXCR4) for stem-cell mobilization.

10 Rituximab was administered during stem-cell mobilization (1 day before chemotherapy at 375

11 dary end points were: overall response rate, stem-cell mobilization activity, and toxicity.

12 c malignancies, and problems associated with stem cell mobilization after lenalidomide treatment.

13 rtaken to evaluate the effect of hemopoietic stem cell mobilization and harvesting on HIV-1 replicati

14 ory process overall as well as hematopoietic stem cell mobilization and homing.

15 ng haematopoietic stem cells, haematopoietic stem cell mobilization and lineage determination and B c

16 own of PHD and FIH synergistically increases stem cell mobilization and myocardial angiogenesis, lead

17 viously unknown signaling pathway regulating stem cell mobilization and provide a new pharmacological

18 he care of patients with diabetes undergoing stem cell mobilization and transplantation and for the v

19 in murine and rhesus monkey peripheral blood stem cell mobilization and transplantation models.

20 ypothesize that neuropathy of the BM affects stem cell mobilization and vascular recovery after ische

21 The impact of VDD on stem-cell mobilization and collection also was evaluated

22 As stem-cell mobilization and in vitro culture techniques h

23 emphases on patient selection, approaches to stem cell mobilization, and peri-SCT management.

24 tors and small molecule CXCR4 antagonist for stem- cell mobilization, and in vivo experimental transp

25 ed that the adverse effects of pharmacologic stem cell mobilization are primarily mediated by the con

26 All patients underwent stem cell mobilization before 1:1 randomization to immun

27 p better define the complicated mechanism of stem cell mobilization by G-CSF and point to a wide role

28 or a range of clinical conditions, including stem cell mobilization, cancer prognosis and treatment,

29 Augmented stem cell mobilization could also be demonstrated in mic

30 s for venous thromboembolism prophylaxis and stem cell mobilization failure associated with lenalidom

31 Is peripheral stem cell mobilization followed by autologous stem cell

32 d the development of therapies to facilitate stem cell mobilization for clinical purposes.

33 drug,Me6TREN, may have broad applications in stem-cell mobilization for cancer and in regenerative me

34 he US Food and Drug Administration (FDA) for stem cell mobilization in cancer and administered for th

35 AMD3100 was recently FDA-approved for stem cell mobilization in combination with granulocyte-c

36 sion, autonomic neuropathy in the BM impairs stem cell mobilization in diabetes with dysregulation of

37 However, the safety and feasibility of stem cell mobilization in individuals with sickle cell t

38 Optimal methods of stem cell mobilization in multiple myeloma are undefined

39 develop renal insufficiency while undergoing stem cell mobilization in preparation for an autologous

40 proliferation and facilitates hematopoietic stem cell mobilization in vivo, while the stromal-derive

41 ors and induces hematopoietic progenitor and stem cell mobilization in vivo.

42 of 2 platelet transfusions was required for stem cell mobilization, intravenous catheter insertion,

43 single injection of both agents resulted in stem cell mobilization peaking within 15 min that was eq

44 uding one who required intubation during his stem cell mobilization period.

45 Pretransplantation R did not affect stem-cell mobilization, post-transplantation early compl

46 Here, we demonstrate that endogenous stem cell mobilization produced by AMD3100 and low-dose

47 onstrate in mice that endogenous bone marrow stem cell mobilization, produced by a pharmacologic comb

48 cing its myeloprotective or peripheral blood stem cell mobilization properties, which can be used to

49 use of granulocytosis-inducing hematopoietic stem cell mobilization protocols for the prevention or t

50 In conclusion, plerixafor results in rapid stem cell mobilization regardless of route of administra

51 We developed a rapid stem cell mobilization regimen utilizing a unique CXCR2

52 eptors, 5-HT(2B), is involved in bone marrow stem cell mobilization that participates in the developm

53 poraneous with filgrastim administration for stem cell mobilization, the patient's slowly progressive

54 f CXCR4 antagonists is an efficient means of stem cell mobilization, this fails to evoke the immunomo

55 f IGF-1 transgene expression induced massive stem cell mobilization via SDF-1alpha signaling and culm

56 Stem cell mobilization was attempted in 88 patients and

57 Toxicity was largely hematologic, and stem cell mobilization was successful in 43 of 45 patien

58 cause anti-CD49d also supports hematopoietic stem cell mobilization, we sought to determine the thera

59 patients who had been primed with VP-16 for stem cell mobilization were at a 12.3-fold increased ris

60 time of ASCT, disease status, and method of stem-cell mobilization, were then analyzed with respect

61 In contrast, stem cell mobilization with the CXCR4 antagonist AMD3100